> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Companies Recall Ranitidine, Nizatidine
- URL: https://www.fdaweb.com/companies-recall-ranitidine-nizatidine/
- Published: 2020-01-09T12:00:00.000Z
- Updated: 2026-09-14T15:58:00.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145805

FDA says Appco Pharma and Denton Pharma (doing business as Northwind Pharmaceuticals) are recalling prescription ranitidine (Zantac) tablets because they may contain unacceptable levels of N-nitrosodimethylamine (NDMA). An agency recall [notice](https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine?utm%5Fcampaign=FDA%20alerts%20patients%20and%20health%20care%20professionals%20to%20two%20voluntary%20recalls%20of%20ranitidine&utm%5Fmedium=email&utm%5Fsource=Eloqua) says FDA has advised companies to recall ranitidine if testing shows NDMA levels above the acceptable daily intake (96 nanograms/day or 0.32 parts per million). The notice says the agency posted the results of its testing ranitidine samples and has asked companies to conduct their own laboratory testing.

FDA also [announced](http://s2027422842.t.en25.com/e/es?s=2027422842&e=291753&elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&elq=bf53ba7086114e038341952639659cbe&elqaid=10857&elqat=1&ref=fdaweb.com) Mylan’s recall of three lots of prescription nizatidine capsules (Axid), a commonly prescribed antacid that is chemically similar to ranitidine, that may contain unacceptable levels of NDMA.